Aspire Biopharma

ASBP

Market cap $10.1M

High-Octane Partnership: Multi-time X Games medalist Jarryd McNeil joins BUZZ BOMB™ to fuel brand expansion in action sports. Consumer Connection: The collaboration strengthens BUZZ BOMB™'s commitment to delivering fast-acting energy to elite athletes and active consumers worldwide.

The brand expands nationwide distribution on Amazon, delivering a waterless, rapid-dissolve 50 mg caffeine powder built for active, on-the-go lifestyles. ESTERO, FL / ACCESS Newswire / June 24, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC today announced the nationwide Amazon launch of its innovative BUZZ BOMB™ 50mg caffeine stick packs.

ESTERO, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- Aspire Biopharma Holdings, Inc.'s (Nasdaq: ASBP) (“Aspire” or the “Company”), today announced that it will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on June 25th, 2026.

Aspire Biopharma Holdings Inc. (NASDAQ:ASBP) shares initially surged on Friday but have since reversed. Here's what you need to know.

Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems Acquisition significantly accelerates Aspire's revenue, earnings growth and cash flow profile Strategically diversifies Aspire's revenue streams Opportunity to drive significant shareholder value creation and enhance long-term capital allocation optionality Company does not anticipate procuring new equity financing to consummate the transaction ESTERO, FL / ACCESS Newswire / June 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced the signing of a definitive Share Purchase Agreement ("SPA") for the acquisition of 100% of Dura Driver Control Systems ("DCS"), a premier designer and manufacturer of automotive driver control systems with expanding industrial applications. The proposed acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise.

ESTERO, FL / ACCESS Newswire / May 28, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today issued the following letter to shareholders from Chief Executive Officer Kraig Higginson. Dear Fellow Shareholders, 2026 is shaping up to be a defining year for Aspire Biopharma Holdings.

ESTERO, FL / ACCESS Newswire / May 27, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC is proud to announce a strategic partnership with EoS Fitness, the High Value. Low Price.

ESTERO, FL / ACCESS Newswire / May 7, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it will effect a one-for-thirty (1:30) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on May 11, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Aspire has requested that its Common Stock begin trading on May 11, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol "ASBP".

ESTERO, FL / ACCESS Newswire / April 27, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that its Board of Directors (the "Board") has authorized the repurchase of up to $5.0 million of the Company's common stock. The authorization reflects the Board's confidence in the Company's balance sheet strength, the value of its drug development pipeline and supplement business, and the potential value creation from the recently announced Binding Letter of Intent (LOI) to acquire Dura Driver Control Systems (DCS).

Company secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition of Dura Control Systems (DCS) LOI to acquire DCS, a leading global automotive supplier with $200M+ in 2025 revenue, is not expected to require new equity raise to consummate the purchase ESTERO, FL / ACCESS Newswire / April 20, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company") today announced that it has closed the second and final tranche of the private placement announced on February 11, 2026 (the "Offering") for the purchase and sale of 26,250 shares of Series A Convertible Preferred Stock. Pursuant to the closing of the second and final tranche of the Offering, the Company issued an aggregate of 12,500 Preferred Shares for gross proceeds of $10.0 million.